Suven Life Sciences has declared dose administration of the first patient in a Phase 2A clinical trial of SUVN G-3031, a Histamine H3 receptor inverse agonist in a Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients with Narcolepsy … Read more
Suven Life Sciences is currently trading at Rs. 295.95, up by 1.70 points or 0.58% from its previous closing of Rs. 294.25 on the BSE. The scrip opened at Rs. 291.00 and has touched a high and low of Rs. 303.80 and Rs. 291.00 respectively. So far 46089 shares were traded on the counter. The … Read more
Suven Life Sciences has received approval to form Wholly Owned Subsidiary (WOS) Company — Suven Pharma, Inc. a Delaware Company in US under CRAMS Division. The Board of Directors of the Company at its meeting held on March 09, 2019 has approved the same. The board also approved investment of $75 million in the said … Read more
Suven Life Science has secured one product patent from Australia and one product patent from Hong Kong corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2033 respectively. The granted claims of the patents include the class of selective M1 PAM and … Read more